LifeCodexx Successfully Completes Clinical Validation of its Noninvasive Prenatal Test Method of Trisomy 21

03-May-2012 - Germany

LifeCodexx AG announced the successful completion of the clinical validation study of its noninvasive test method for the detection of fetal trisomy 21 from maternal blood using Next Generation sequencing. First results from the prospective blinded multi-center study demonstrate highest clinical accuracy for the planned commercial PraenaTest® test design based on Cell-Free DNA™ blood collection tubes (BCT), detecting all positive cases of fetal trisomy 21 (100% sensitivity) with no false negative calls (100% specificity).

During the study, five prenatal centers and university hospitals in Germany and Switzerland recruited a total of 522 maternal blood samples from pregnant women with high risk of chromosomal alterations in the unborn child. Gestational age ranged from week 11+0 to 32+1. The main goal of the study was to compare detection rates for trisomy 21 of a test method based on Next Generation sequencing using maternal blood with conventional karyotyping using invasive methods, e.g. amniocentesis or chorionic villus sampling. For the study, maternal blood was sampled in two different ways, either using regular K 3 EDTA blood collection tubes or Cell-Free DNA™ blood collection tubes (BCT). While for the K3 EDTA blood collection tubes the study centers had to prepare blood plasma at their sites before shipment, the use of Cell-Free DNA™ BCT required direct dispatch to LifeCodexx without any prior preparation work at the physician´s site.

First-cut analysis of the full set of recruited samples with 42 positive trisomy 21 cases showed an overall clinical sensitivity of 95% and specificity of 99.5%. However, a more detailed analysis revealed substantial differences between the blood sampling methods with regard to clinical sensitivity and specificity. The results of the blood samples which were stabilised in K3 EDTA blood collection tubes achieved a sensitivity rate of 81.8% and a specificity rate of 98.7% only. In contrast, blood sampling using Cell-Free DNA™ BCT yielded far better results with 100% clinical sensitivity and specificity. Cell-Free DNA™ blood collection tubes preserve cell-free DNA circulating in plasma, allowing sample collection and shipment at room temperature without any additional preparation work at the phycisians’ site.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures